المؤلفون: Nalder M., Kennedy E., Smith C.L., Yip D., Williams A., Low J.K., Manias E., Crawford K., Walker R., Mulley W.R., Toussaint N.D., Dooley M.

مصطلحات الفهرس: clinical trial, comparative study, controlled study, counseling, female, graft rejection/pc [Prevention], human, kidney transplantation, male, medication compliance, middle aged, multicenter study, patient education, pilot study, public hospital, randomized controlled trial, single blind procedure, telemedicine, telephone, treatment outcome, Victoria, immunosuppressive agent/dt [Drug Therapy], tacrolimus/dt [Drug Therapy], adult, audiovisual aid, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35508
Click here for full text options
LibKey Link

المؤلفون: Anders H.-J., Merkel P.A., Savage C.O.S., Specks U., Kain R., Jayne D.R., Lyons P.A., Gordon J., Kitching A.R., Brouwer E., Basu N., Kullman J.

مصطلحات الفهرس: infection, kidney disease, macrophage, maintenance therapy, microscopic polyangiitis, monocyte, neutrophil, nonhuman, pathogenesis, pathophysiology, prevalence, priority journal, prognosis, quality of life, respiratory tract disease, review, risk factor, screening, T lymphocyte, treatment duration, Wegener granulomatosis/dt [Drug Therapy], Wegener granulomatosis/et [Etiology], autoantigen/ec [Endogenous Compound], biological marker/ec [Endogenous Compound], cyclophosphamide/dt [Drug Therapy], glucocorticoid/dt [Drug Therapy], immunoglobulin/dt [Drug Therapy], immunomodulating agent/dt [Drug Therapy], immunosuppressive agent/dt [Drug Therapy], mepolizumab/dt [Drug Therapy], methylprednisolone/dt [Drug Therapy], neutrophil cytoplasmic antibody/ec [Endogenous Compound], rituximab/dt [Drug Therapy], eosinophilic granulomatosis with polyangiitis/dt [Drug Therapy], microvasculature, ANCA associated vasculitis/di [Diagnosis], ANCA associated vasculitis/dm [Disease Management], ANCA associated vasculitis/dt [Drug Therapy], ANCA associated vasculitis/ep [Epidemiology], ANCA associated vasculitis/et [Etiology], ANCA associated vasculitis/pc [Prevention], B lymphocyte, biopsy, cardiovascular disease, cellular immunity, clinical feature, clinical trial (topic), comorbidity, complement activation, diagnostic imaging, disease activity, disease association, disease classification, disease severity, environmental factor, genetics, human, incidence, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29087
Click here for full text options
LibKey Link

المؤلفون: Ooi J.D., Eggenhuizen P.J., Ng B.H.

مصطلحات الفهرس: Crohn disease/th [Therapy], dendritic cell, DNA immunization, DNA vector, drug targeting, effector cell, fecal microbiota transplantation, graft rejection, immunological tolerance, insulin dependent diabetes mellitus/dt [Drug Therapy], insulin dependent diabetes mellitus/et [Etiology], low drug dose, microbiome, multiple sclerosis/et [Etiology], nonhuman, pemphigus/th [Therapy], phenotype, regulatory T lymphocyte, review, skin lupus erythematosus/th [Therapy], synergistic effect, systemic lupus erythematosus/et [Etiology], T lymphocyte subpopulation, transient expression, treatment outcome, umbilical cord blood, aldesleukin/dt [Drug Therapy], autoantigen, bacterial polysaccharide, beta glucan, butyric acid, CD135 antigen, chimeric antigen receptor/ec [Endogenous Compound], corticosteroid/dt [Drug Therapy], cytokine receptor agonist/dt [Drug Therapy], cytokine receptor agonist/pd [Pharmacology], cytotoxic T lymphocyte antigen 4/ec [Endogenous Compound], Flt3 ligand/cb [Drug Combination], Flt3 ligand/it [Drug Interaction], Flt3 ligand/dt [Drug Therapy], galactan, immunosuppressive agent/dt [Drug Therapy], insulin/dt [Drug Therapy], interleukin 10/dt [Drug Therapy], interleukin 10/pd [Pharmacology], major histocompatibility antigen/ec [Endogenous Compound], mammalian target of rapamycin/ec [Endogenous Compound], mammalian target of rapamycin inhibitor/dt [Drug Therapy], mammalian target of rapamycin inhibitor/pd [Pharmacology], methylprednisolone/do [Drug Dose], methylprednisolone/dt [Drug Therapy], mycophenolic acid/do [Drug Dose], mycophenolic acid/dt [Drug Therapy], nanoparticle, peptide/dt [Drug Therapy], rapamycin/cb [Drug Combination], rapamycin/it [Drug Interaction], rapamycin/dt [Drug Therapy], rapamycin/pd [Pharmacology], recombinant interleukin 2/do [Drug Dose], recombinant interleukin 2/dt [Drug Therapy], short chain fatty acid, T lymphocyte receptor/ec [Endogenous Compound], tacrolimus/do [Drug Dose], tacrolimus/dt [Drug Therapy], transcription factor FOXP3/ec [Endogenous Compound], tumor necrosis factor receptor 2/ec [Endogenous Compound], unclassified drug, tumor necrosis factor receptor 2 agonist/dt [Drug Therapy], tumor necrosis factor receptor 2 agonist/pd [Pharmacology], human, adverse event, antigen specificity, antiinflammatory activity, autoimmune disease/dt [Drug Therapy], autoimmune disease/et [Etiology], autoimmune disease/pc [Prevention], autoimmune disease/th [Therapy], autoimmune hepatitis/th [Therapy], autoimmunity, Bifidobacterium bifidum, biological therapy, CD4+ T lymphocyte, cell therapy, chimeric antigen receptor immunotherapy, chronic inflammation, Review

URL: International Journal of Molecular Sciences
Click here for full text options
LibKey Link

المؤلفون: Kandane-Rathnayake R., Huq M., Yeo A.L., Hammond E., Nab H., Nikpour M., Morand E.F., Hoi A., Golder V., Koelmeyer R.

مصطلحات الفهرس: immunosuppressive agent/pe [Pharmacoeconomics], prednisolone/dt [Drug Therapy], prednisolone/pe [Pharmacoeconomics], American College of Rheumatology Damage Index, flare index, lupus low disease activity state, Physician Global Assessment, Systemic Lupus International Collaborating Clinic, human, adult, article, cohort analysis, controlled study, demography, drug cost, drug use, female, health care cost, health care utilization, hospital information system, longitudinal study, lupus erythematosus nephritis, major clinical study, male, medical history, scoring system, SLEDAI, systemic lupus erythematosus/dm [Disease Management], systemic lupus erythematosus/dt [Drug Therapy], tertiary care center, immunosuppressive agent/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29084
Arthritis Care and Research
LibKey Link

المؤلفون: Nalder M., Kennedy E., Smith C.L., Yip D., Williams A., Low J.K., Manias E., Crawford K., Walker R., Mulley W.R., Toussaint N.D., Dooley M.

مصطلحات الفهرس: clinical trial, comparative study, controlled study, counseling, female, graft rejection/pc [Prevention], human, kidney transplantation, male, medication compliance, middle aged, multicenter study, patient education, pilot study, public hospital, randomized controlled trial, single blind procedure, telemedicine, telephone, treatment outcome, Victoria, immunosuppressive agent/dt [Drug Therapy], tacrolimus/dt [Drug Therapy], adult, audiovisual aid, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35508
Scientific Reports
LibKey Link

المؤلفون: Anders H.-J., Merkel P.A., Savage C.O.S., Specks U., Kain R., Jayne D.R., Lyons P.A., Gordon J., Kitching A.R., Brouwer E., Basu N., Kullman J.

مصطلحات الفهرس: infection, kidney disease, macrophage, maintenance therapy, microscopic polyangiitis, monocyte, neutrophil, nonhuman, pathogenesis, pathophysiology, prevalence, priority journal, prognosis, quality of life, respiratory tract disease, review, risk factor, screening, T lymphocyte, treatment duration, Wegener granulomatosis/dt [Drug Therapy], Wegener granulomatosis/et [Etiology], autoantigen/ec [Endogenous Compound], biological marker/ec [Endogenous Compound], cyclophosphamide/dt [Drug Therapy], glucocorticoid/dt [Drug Therapy], immunoglobulin/dt [Drug Therapy], immunomodulating agent/dt [Drug Therapy], immunosuppressive agent/dt [Drug Therapy], mepolizumab/dt [Drug Therapy], methylprednisolone/dt [Drug Therapy], neutrophil cytoplasmic antibody/ec [Endogenous Compound], rituximab/dt [Drug Therapy], eosinophilic granulomatosis with polyangiitis/dt [Drug Therapy], microvasculature, ANCA associated vasculitis/di [Diagnosis], ANCA associated vasculitis/dm [Disease Management], ANCA associated vasculitis/dt [Drug Therapy], ANCA associated vasculitis/ep [Epidemiology], ANCA associated vasculitis/et [Etiology], ANCA associated vasculitis/pc [Prevention], B lymphocyte, biopsy, cardiovascular disease, cellular immunity, clinical feature, clinical trial (topic), comorbidity, complement activation, diagnostic imaging, disease activity, disease association, disease classification, disease severity, environmental factor, genetics, human, incidence, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29087
Nature Reviews Disease Primers
LibKey Link

المؤلفون: Ooi J.D., Eggenhuizen P.J., Ng B.H.

مصطلحات الفهرس: Crohn disease/th [Therapy], dendritic cell, DNA immunization, DNA vector, drug targeting, effector cell, fecal microbiota transplantation, graft rejection, immunological tolerance, insulin dependent diabetes mellitus/dt [Drug Therapy], insulin dependent diabetes mellitus/et [Etiology], low drug dose, microbiome, multiple sclerosis/et [Etiology], nonhuman, pemphigus/th [Therapy], phenotype, regulatory T lymphocyte, review, skin lupus erythematosus/th [Therapy], synergistic effect, systemic lupus erythematosus/et [Etiology], T lymphocyte subpopulation, transient expression, treatment outcome, umbilical cord blood, aldesleukin/dt [Drug Therapy], autoantigen, bacterial polysaccharide, beta glucan, butyric acid, CD135 antigen, chimeric antigen receptor/ec [Endogenous Compound], corticosteroid/dt [Drug Therapy], cytokine receptor agonist/dt [Drug Therapy], cytokine receptor agonist/pd [Pharmacology], cytotoxic T lymphocyte antigen 4/ec [Endogenous Compound], Flt3 ligand/cb [Drug Combination], Flt3 ligand/it [Drug Interaction], Flt3 ligand/dt [Drug Therapy], galactan, immunosuppressive agent/dt [Drug Therapy], insulin/dt [Drug Therapy], interleukin 10/dt [Drug Therapy], interleukin 10/pd [Pharmacology], major histocompatibility antigen/ec [Endogenous Compound], mammalian target of rapamycin/ec [Endogenous Compound], mammalian target of rapamycin inhibitor/dt [Drug Therapy], mammalian target of rapamycin inhibitor/pd [Pharmacology], methylprednisolone/do [Drug Dose], methylprednisolone/dt [Drug Therapy], mycophenolic acid/do [Drug Dose], mycophenolic acid/dt [Drug Therapy], nanoparticle, peptide/dt [Drug Therapy], rapamycin/cb [Drug Combination], rapamycin/it [Drug Interaction], rapamycin/dt [Drug Therapy], rapamycin/pd [Pharmacology], recombinant interleukin 2/do [Drug Dose], recombinant interleukin 2/dt [Drug Therapy], short chain fatty acid, T lymphocyte receptor/ec [Endogenous Compound], tacrolimus/do [Drug Dose], tacrolimus/dt [Drug Therapy], transcription factor FOXP3/ec [Endogenous Compound], tumor necrosis factor receptor 2/ec [Endogenous Compound], unclassified drug, tumor necrosis factor receptor 2 agonist/dt [Drug Therapy], tumor necrosis factor receptor 2 agonist/pd [Pharmacology], human, adverse event, antigen specificity, antiinflammatory activity, autoimmune disease/dt [Drug Therapy], autoimmune disease/et [Etiology], autoimmune disease/pc [Prevention], autoimmune disease/th [Therapy], autoimmune hepatitis/th [Therapy], autoimmunity, Bifidobacterium bifidum, biological therapy, CD4+ T lymphocyte, cell therapy, chimeric antigen receptor immunotherapy, chronic inflammation, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29021
International Journal of Molecular Sciences
LibKey Link

المؤلفون: Holdsworth S.R., Olson G.L., Rao N.B., Self C.R., Sun Y., Ooi J.D., Kitching A.R., Huynh M., Eggenhuizen P.J.

مصطلحات الفهرس: article, autoimmunity, cell infiltration, controlled study, disease course, enzyme linked immunospot assay, female, glomerulonephritis/dt [Drug Therapy], histology, immune response, immunization, immunoreactivity, kidney injury, lymphocyte proliferation, male, mouse, nonhuman, priority journal, T lymphocyte, epitope, gamma interferon/ec [Endogenous Compound], HLA DR15 antigen/ec [Endogenous Compound], immunoglobulin G/ec [Endogenous Compound], immunosuppressive agent/dt [Drug Therapy], immunosuppressive agent/ip [Intraperitoneal Drug Administration], immunosuppressive agent/pd [Pharmacology], interleukin 17/ec [Endogenous Compound], unclassified drug, PV 267/dt [Drug Therapy], PV 267/pd [Pharmacology], PV 267/ip [Intraperitoneal Drug Administration], albuminuria, animal experiment, animal model, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/36007
Journal of Autoimmunity
Click here for full text options
LibKey Link

المؤلفون: Alex G., Buckton S., Page A.T., Stocks N., Cameron D., Manglaviti F., Pavli P., Massuger W., Moore G.T.C., Andrews J.M., Kilkenny M.F., Reyneke M., Knowles S., Purcell L.

مصطلحات الفهرس: anemia, newborn, patient care, priority journal, protocol compliance, retrospective study, treatment failure, ulcerative colitis/dt [Drug Therapy], biological product/dt [Drug Therapy], corticosteroid/dt [Drug Therapy], immunosuppressive agent/dt [Drug Therapy], abscess drainage, adolescent, adult, aged, article, Australia, child, clinical audit, colon resection, controlled study, Crohn disease/dt [Drug Therapy], cross-sectional study, disease duration, documentation, female, health care quality, health service, hospital admission, hospital discharge, hospital patient, hospital readmission, human, infant, intestine obstruction, length of stay, major clinical study, male, Article

URL: Internal Medicine Journal
Click here for full text options
LibKey Link

المؤلفون: Holdsworth S.R., Olson G.L., Rao N.B., Self C.R., Sun Y., Ooi J.D., Kitching A.R., Huynh M., Eggenhuizen P.J.

مصطلحات الفهرس: article, autoimmunity, cell infiltration, controlled study, disease course, enzyme linked immunospot assay, female, glomerulonephritis/dt [Drug Therapy], histology, immune response, immunization, immunoreactivity, kidney injury, lymphocyte proliferation, male, mouse, nonhuman, priority journal, T lymphocyte, epitope, gamma interferon/ec [Endogenous Compound], HLA DR15 antigen/ec [Endogenous Compound], immunoglobulin G/ec [Endogenous Compound], immunosuppressive agent/dt [Drug Therapy], immunosuppressive agent/ip [Intraperitoneal Drug Administration], immunosuppressive agent/pd [Pharmacology], interleukin 17/ec [Endogenous Compound], unclassified drug, PV 267/dt [Drug Therapy], PV 267/pd [Pharmacology], PV 267/ip [Intraperitoneal Drug Administration], albuminuria, animal experiment, animal model, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/36007
Journal of Autoimmunity
LibKey Link

المؤلفون: Alex G., Buckton S., Page A.T., Stocks N., Cameron D., Manglaviti F., Pavli P., Massuger W., Moore G.T.C., Andrews J.M., Kilkenny M.F., Reyneke M., Knowles S., Purcell L.

مصطلحات الفهرس: anemia, newborn, patient care, priority journal, protocol compliance, retrospective study, treatment failure, ulcerative colitis/dt [Drug Therapy], biological product/dt [Drug Therapy], corticosteroid/dt [Drug Therapy], immunosuppressive agent/dt [Drug Therapy], abscess drainage, adolescent, adult, aged, article, Australia, child, clinical audit, colon resection, controlled study, Crohn disease/dt [Drug Therapy], cross-sectional study, disease duration, documentation, female, health care quality, health service, hospital admission, hospital discharge, hospital patient, hospital readmission, human, infant, intestine obstruction, length of stay, major clinical study, male, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35609
Internal Medicine Journal
LibKey Link

المؤلفون: Ho G.T., Satsangi J., Boyapati R.K.

مصطلحات الفهرس: mercaptopurine/dt [Drug Therapy], clinical research, Crohn disease/dt [Drug Therapy], disease control, disease marker, editorial, high risk patient, human, intensive care, maintenance therapy, medical decision making, personalized medicine, priority journal, remission, symptom, azathioprine/dt [Drug Therapy], biological product/dt [Drug Therapy], immunosuppressive agent/dt [Drug Therapy], infliximab/dt [Drug Therapy], methotrexate/dt [Drug Therapy], tumor necrosis factor inhibitor/dt [Drug Therapy], ustekinumab/dt [Drug Therapy], vedolizumab/dt [Drug Therapy], Editorial

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37332
Journal of Crohn's and Colitis
Click here for full text options
LibKey Link

المؤلفون: Rischmueller M., Mackay F., Morand E.F., Vincent F.B., Kandane-Rathnayake R., Hoi A.Y., Slavin L., Godsell J.D., Kitching A.R., Harris J., Nelson C.L., Jenkins A.J., Chrysostomou A., Hibbs M.L., Kerr P.G.

مصطلحات الفهرس: systemic lupus erythematosus/dt [Drug Therapy], urine sampling, APRIL protein/ec [Endogenous Compound], B cell activating factor/ec [Endogenous Compound], C reactive protein/ec [Endogenous Compound], double stranded DNA antibody/ec [Endogenous Compound], glucocorticoid/dt [Drug Therapy], hemoglobin/ec [Endogenous Compound], hydroxychloroquine/dt [Drug Therapy], immunosuppressive agent/dt [Drug Therapy], monocyte chemotactic protein 1/ec [Endogenous Compound], tumor necrosis factor/ec [Endogenous Compound], creatinine urine level, adult, antibody titer, article, controlled study, diagnostic test accuracy study, disease duration, enzyme linked immunosorbent assay, estimated glomerular filtration rate, female, fibrosing alveolitis, follow up, hematuria, human, human tissue, immunoglobulin A nephropathy, kidney biopsy, major clinical study, male, middle aged, nephritis, priority journal, proteinuria, pyuria, sensitivity and specificity, Sjoegren syndrome, SLEDAI, systemic lupus erythematosus/di [Diagnosis], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37296
Lupus
Click here for full text options
LibKey Link

المؤلفون: Colombel J.-F., Palmela C., Parker C.E., Silverberg O.M., Upadhyaya S.D., Nguyen T.M., Boyapati R.K., Torres J.

مصطلحات الفهرس: biological therapy, cohort analysis, controlled clinical trial (topic), Crohn disease/dt [Drug Therapy], drug blood level, drug dose regimen, drug safety, feasibility study, fistula/co [Complication], headache/si [Side Effect], hospitalization, human, hypertransaminasemia/si [Side Effect], infection/si [Side Effect], infusion related reaction/si [Side Effect], leukopenia/si [Side Effect], maintenance therapy, monotherapy, priority journal, prospective study, randomized controlled trial (topic), relapse, review, systematic review, treatment withdrawal, azathioprine/ae [Adverse Drug Reaction], azathioprine/cb [Drug Combination], C reactive protein/ec [Endogenous Compound], calgranulin/ec [Endogenous Compound], immunosuppressive agent/dt [Drug Therapy], infliximab/ae [Adverse Drug Reaction], infliximab/cb [Drug Combination], infliximab/dt [Drug Therapy], azathioprine/dt [Drug Therapy], abdominal disease/si [Side Effect], abscess/co [Complication], arthralgia/si [Side Effect], Review

URL: Cochrane Database of Systematic Reviews
Click here for full text options
LibKey Link

المؤلفون: Strippoli G.F.M., Masson P., Craig J.C., Tong A., Singh-Grewal D., Flanc R.S., Roberts M.A., Webster A.C., Tunnicliffe D.J., Palmer S.C., Henderson L.

مصطلحات الفهرس: leukopenia/si [Side Effect], low drug dose, lupus erythematosus nephritis/dt [Drug Therapy], lupus erythematosus nephritis/th [Therapy], maintenance therapy, malignant neoplasm/si [Side Effect], menstrual irregularity/si [Side Effect], morning dosage, multiple cycle treatment, nausea/si [Side Effect], ovary insufficiency/si [Side Effect], plasma exchange, priority journal, proteinuria, randomized controlled trial (topic), relapse, remission, review, SLEDAI, systematic review, vomiting/si [Side Effect], abatacept/ae [Adverse Drug Reaction], abatacept/ct [Clinical Trial], abatacept/cb [Drug Combination], abatacept/cm [Drug Comparison], abatacept/dt [Drug Therapy], atacicept/ct [Clinical Trial], atacicept/cb [Drug Combination], atacicept/cm [Drug Comparison], atacicept/dt [Drug Therapy], azathioprine/ae [Adverse Drug Reaction], azathioprine/ct [Clinical Trial], azathioprine/cb [Drug Combination], azathioprine/cm [Drug Comparison], azathioprine/dt [Drug Therapy], azathioprine/po [Oral Drug Administration], calcineurin inhibitor/ae [Adverse Drug Reaction], calcineurin inhibitor/ct [Clinical Trial], calcineurin inhibitor/cb [Drug Combination], calcineurin inhibitor/cm [Drug Comparison], calcineurin inhibitor/dt [Drug Therapy], corticosteroid/ae [Adverse Drug Reaction], corticosteroid/ct [Clinical Trial], corticosteroid/ad [Drug Administration], corticosteroid/cb [Drug Combination], corticosteroid/dt [Drug Therapy], corticosteroid/iv [Intravenous Drug Administration], corticosteroid/po [Oral Drug Administration], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/ct [Clinical Trial], cyclophosphamide/ad [Drug Administration], cyclophosphamide/cb [Drug Combination], cyclophosphamide/cm [Drug Comparison], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], cyclophosphamide/po [Oral Drug Administration], cyclosporine/ct [Clinical Trial], cyclosporine/cb [Drug Combination], cyclosporine/cm [Drug Comparison], cyclosporine/dt [Drug Therapy], cyclosporine/po [Oral Drug Administration], glucocorticoid/cb [Drug Combination], glucocorticoid/dt [Drug Therapy], glucocorticoid/po [Oral Drug Administration], immunoglobulin/ct [Clinical Trial], immunoglobulin/cm [Drug Comparison], immunoglobulin/dt [Drug Therapy], immunoglobulin/iv [Intravenous Drug Administration], immunosuppressive agent/ct [Clinical Trial], immunosuppressive agent/cb [Drug Combination], immunosuppressive agent/cm [Drug Comparison], immunosuppressive agent/dt [Drug Therapy], immunosuppressive agent/sc [Subcutaneous Drug Administration], laquinimod/ct [Clinical Trial], laquinimod/cb [Drug Combination], laquinimod/cm [Drug Comparison], laquinimod/dt [Drug Therapy], laquinimod/po [Oral Drug Administration], leflunomide/ct [Clinical Trial], leflunomide/cb [Drug Combination], leflunomide/cm [Drug Comparison], leflunomide/dt [Drug Therapy], leflunomide/po [Oral Drug Administration], methylprednisolone/ct [Clinical Trial], methylprednisolone/cb [Drug Combination], methylprednisolone/cm [Drug Comparison], methylprednisolone/dt [Drug Therapy], methylprednisolone/iv [Intravenous Drug Administration], misoprostol/ct [Clinical Trial], misoprostol/cb [Drug Combination], misoprostol/cm [Drug Comparison], misoprostol/dt [Drug Therapy], misoprostol/po [Oral Drug Administration], mycophenolate mofetil/ae [Adverse Drug Reaction], mycophenolate mofetil/ct [Clinical Trial], mycophenolate mofetil/cb [Drug Combination], mycophenolate mofetil/cm [Drug Comparison], mycophenolate mofetil/dt [Drug Therapy], mycophenolate mofetil/po [Oral Drug Administration], mycophenolic acid/ct [Clinical Trial], mycophenolic acid/cb [Drug Combination], mycophenolic acid/dt [Drug Therapy], ocrelizumab/ae [Adverse Drug Reaction], ocrelizumab/ct [Clinical Trial], ocrelizumab/cb [Drug Combination], ocrelizumab/cm [Drug Comparison], ocrelizumab/dt [Drug Therapy], placebo, prednisolone/ct [Clinical Trial], prednisolone/cb [Drug Combination], prednisolone/cm [Drug Comparison], prednisolone/dt [Drug Therapy], prednisolone/po [Oral Drug Administration], prednisone/ae [Adverse Drug Reaction], prednisone/ct [Clinical Trial], prednisone/cb [Drug Combination], prednisone/cm [Drug Comparison], prednisone/dt [Drug Therapy], prednisone/po [Oral Drug Administration], rituximab/ae [Adverse Drug Reaction], rituximab/ct [Clinical Trial], rituximab/cb [Drug Combination], rituximab/cm [Drug Comparison], rituximab/dt [Drug Therapy], sirukumab/ae [Adverse Drug Reaction], sirukumab/ct [Clinical Trial], sirukumab/cb [Drug Combination], sirukumab/cm [Drug Comparison], sirukumab/dt [Drug Therapy], sirukumab/iv [Intravenous Drug Administration], tacrolimus/ae [Adverse Drug Reaction], tacrolimus/ct [Clinical Trial], tacrolimus/cb [Drug Combination], tacrolimus/cm [Drug Comparison], tacrolimus/dt [Drug Therapy], tacrolimus/po [Oral Drug Administration], unclassified drug, voclosporin/ct [Clinical Trial], voclosporin/cb [Drug Combination], voclosporin/cm [Drug Comparison], voclosporin/dt [Drug Therapy], AMG 811/ct [Clinical Trial], AMG 811/cm [Drug Comparison], AMG 811/sc [Subcutaneous Drug Administration], AMG 811/dt [Drug Therapy], all cause mortality, alopecia/si [Side Effect], biological therapy, bladder disease/si [Side Effect], bone disease/si [Side Effect], creatinine blood level, creatinine clearance, diarrhea/si [Side Effect], disease activity, dosage schedule comparison, drug dose comparison, drug dose increase, drug dose reduction, drug dose titration, drug megadose, drug withdrawal, end stage renal disease, gastrointestinal symptom/si [Side Effect], herpes zoster/si [Side Effect], human, immunoadsorption, immunosuppressive treatment, infection/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37602
Cochrane Database of Systematic Reviews
Click here for full text options
LibKey Link

المؤلفون: Ho G.T., Satsangi J., Boyapati R.K.

مصطلحات الفهرس: mercaptopurine/dt [Drug Therapy], clinical research, Crohn disease/dt [Drug Therapy], disease control, disease marker, editorial, high risk patient, human, intensive care, maintenance therapy, medical decision making, personalized medicine, priority journal, remission, symptom, azathioprine/dt [Drug Therapy], biological product/dt [Drug Therapy], immunosuppressive agent/dt [Drug Therapy], infliximab/dt [Drug Therapy], methotrexate/dt [Drug Therapy], tumor necrosis factor inhibitor/dt [Drug Therapy], ustekinumab/dt [Drug Therapy], vedolizumab/dt [Drug Therapy], Editorial

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37332
Journal of Crohn's and Colitis
Click here for full text options
LibKey Link

المؤلفون: Rischmueller M., Mackay F., Morand E.F., Vincent F.B., Kandane-Rathnayake R., Hoi A.Y., Slavin L., Godsell J.D., Kitching A.R., Harris J., Nelson C.L., Jenkins A.J., Chrysostomou A., Hibbs M.L., Kerr P.G.

مصطلحات الفهرس: systemic lupus erythematosus/dt [Drug Therapy], urine sampling, APRIL protein/ec [Endogenous Compound], B cell activating factor/ec [Endogenous Compound], C reactive protein/ec [Endogenous Compound], double stranded DNA antibody/ec [Endogenous Compound], glucocorticoid/dt [Drug Therapy], hemoglobin/ec [Endogenous Compound], hydroxychloroquine/dt [Drug Therapy], immunosuppressive agent/dt [Drug Therapy], monocyte chemotactic protein 1/ec [Endogenous Compound], tumor necrosis factor/ec [Endogenous Compound], creatinine urine level, adult, antibody titer, article, controlled study, diagnostic test accuracy study, disease duration, enzyme linked immunosorbent assay, estimated glomerular filtration rate, female, fibrosing alveolitis, follow up, hematuria, human, human tissue, immunoglobulin A nephropathy, kidney biopsy, major clinical study, male, middle aged, nephritis, priority journal, proteinuria, pyuria, sensitivity and specificity, Sjoegren syndrome, SLEDAI, systemic lupus erythematosus/di [Diagnosis], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37296
Lupus
Click here for full text options
LibKey Link

المؤلفون: Colombel J.-F., Palmela C., Parker C.E., Silverberg O.M., Upadhyaya S.D., Nguyen T.M., Boyapati R.K., Torres J.

مصطلحات الفهرس: biological therapy, cohort analysis, controlled clinical trial (topic), Crohn disease/dt [Drug Therapy], drug blood level, drug dose regimen, drug safety, feasibility study, fistula/co [Complication], headache/si [Side Effect], hospitalization, human, hypertransaminasemia/si [Side Effect], infection/si [Side Effect], infusion related reaction/si [Side Effect], leukopenia/si [Side Effect], maintenance therapy, monotherapy, priority journal, prospective study, randomized controlled trial (topic), relapse, review, systematic review, treatment withdrawal, azathioprine/ae [Adverse Drug Reaction], azathioprine/cb [Drug Combination], C reactive protein/ec [Endogenous Compound], calgranulin/ec [Endogenous Compound], immunosuppressive agent/dt [Drug Therapy], infliximab/ae [Adverse Drug Reaction], infliximab/cb [Drug Combination], infliximab/dt [Drug Therapy], azathioprine/dt [Drug Therapy], abdominal disease/si [Side Effect], abscess/co [Complication], arthralgia/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37604
Cochrane Database of Systematic Reviews
Click here for full text options
LibKey Link

المؤلفون: Strippoli G.F.M., Masson P., Craig J.C., Tong A., Singh-Grewal D., Flanc R.S., Roberts M.A., Webster A.C., Tunnicliffe D.J., Palmer S.C., Henderson L.

مصطلحات الفهرس: leukopenia/si [Side Effect], low drug dose, lupus erythematosus nephritis/dt [Drug Therapy], lupus erythematosus nephritis/th [Therapy], maintenance therapy, malignant neoplasm/si [Side Effect], menstrual irregularity/si [Side Effect], morning dosage, multiple cycle treatment, nausea/si [Side Effect], ovary insufficiency/si [Side Effect], plasma exchange, priority journal, proteinuria, randomized controlled trial (topic), relapse, remission, review, SLEDAI, systematic review, vomiting/si [Side Effect], abatacept/ae [Adverse Drug Reaction], abatacept/ct [Clinical Trial], abatacept/cb [Drug Combination], abatacept/cm [Drug Comparison], abatacept/dt [Drug Therapy], atacicept/ct [Clinical Trial], atacicept/cb [Drug Combination], atacicept/cm [Drug Comparison], atacicept/dt [Drug Therapy], azathioprine/ae [Adverse Drug Reaction], azathioprine/ct [Clinical Trial], azathioprine/cb [Drug Combination], azathioprine/cm [Drug Comparison], azathioprine/dt [Drug Therapy], azathioprine/po [Oral Drug Administration], calcineurin inhibitor/ae [Adverse Drug Reaction], calcineurin inhibitor/ct [Clinical Trial], calcineurin inhibitor/cb [Drug Combination], calcineurin inhibitor/cm [Drug Comparison], calcineurin inhibitor/dt [Drug Therapy], corticosteroid/ae [Adverse Drug Reaction], corticosteroid/ct [Clinical Trial], corticosteroid/ad [Drug Administration], corticosteroid/cb [Drug Combination], corticosteroid/dt [Drug Therapy], corticosteroid/iv [Intravenous Drug Administration], corticosteroid/po [Oral Drug Administration], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/ct [Clinical Trial], cyclophosphamide/ad [Drug Administration], cyclophosphamide/cb [Drug Combination], cyclophosphamide/cm [Drug Comparison], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], cyclophosphamide/po [Oral Drug Administration], cyclosporine/ct [Clinical Trial], cyclosporine/cb [Drug Combination], cyclosporine/cm [Drug Comparison], cyclosporine/dt [Drug Therapy], cyclosporine/po [Oral Drug Administration], glucocorticoid/cb [Drug Combination], glucocorticoid/dt [Drug Therapy], glucocorticoid/po [Oral Drug Administration], immunoglobulin/ct [Clinical Trial], immunoglobulin/cm [Drug Comparison], immunoglobulin/dt [Drug Therapy], immunoglobulin/iv [Intravenous Drug Administration], immunosuppressive agent/ct [Clinical Trial], immunosuppressive agent/cb [Drug Combination], immunosuppressive agent/cm [Drug Comparison], immunosuppressive agent/dt [Drug Therapy], immunosuppressive agent/sc [Subcutaneous Drug Administration], laquinimod/ct [Clinical Trial], laquinimod/cb [Drug Combination], laquinimod/cm [Drug Comparison], laquinimod/dt [Drug Therapy], laquinimod/po [Oral Drug Administration], leflunomide/ct [Clinical Trial], leflunomide/cb [Drug Combination], leflunomide/cm [Drug Comparison], leflunomide/dt [Drug Therapy], leflunomide/po [Oral Drug Administration], methylprednisolone/ct [Clinical Trial], methylprednisolone/cb [Drug Combination], methylprednisolone/cm [Drug Comparison], methylprednisolone/dt [Drug Therapy], methylprednisolone/iv [Intravenous Drug Administration], misoprostol/ct [Clinical Trial], misoprostol/cb [Drug Combination], misoprostol/cm [Drug Comparison], misoprostol/dt [Drug Therapy], misoprostol/po [Oral Drug Administration], mycophenolate mofetil/ae [Adverse Drug Reaction], mycophenolate mofetil/ct [Clinical Trial], mycophenolate mofetil/cb [Drug Combination], mycophenolate mofetil/cm [Drug Comparison], mycophenolate mofetil/dt [Drug Therapy], mycophenolate mofetil/po [Oral Drug Administration], mycophenolic acid/ct [Clinical Trial], mycophenolic acid/cb [Drug Combination], mycophenolic acid/dt [Drug Therapy], ocrelizumab/ae [Adverse Drug Reaction], ocrelizumab/ct [Clinical Trial], ocrelizumab/cb [Drug Combination], ocrelizumab/cm [Drug Comparison], ocrelizumab/dt [Drug Therapy], placebo, prednisolone/ct [Clinical Trial], prednisolone/cb [Drug Combination], prednisolone/cm [Drug Comparison], prednisolone/dt [Drug Therapy], prednisolone/po [Oral Drug Administration], prednisone/ae [Adverse Drug Reaction], prednisone/ct [Clinical Trial], prednisone/cb [Drug Combination], prednisone/cm [Drug Comparison], prednisone/dt [Drug Therapy], prednisone/po [Oral Drug Administration], rituximab/ae [Adverse Drug Reaction], rituximab/ct [Clinical Trial], rituximab/cb [Drug Combination], rituximab/cm [Drug Comparison], rituximab/dt [Drug Therapy], sirukumab/ae [Adverse Drug Reaction], sirukumab/ct [Clinical Trial], sirukumab/cb [Drug Combination], sirukumab/cm [Drug Comparison], sirukumab/dt [Drug Therapy], sirukumab/iv [Intravenous Drug Administration], tacrolimus/ae [Adverse Drug Reaction], tacrolimus/ct [Clinical Trial], tacrolimus/cb [Drug Combination], tacrolimus/cm [Drug Comparison], tacrolimus/dt [Drug Therapy], tacrolimus/po [Oral Drug Administration], unclassified drug, voclosporin/ct [Clinical Trial], voclosporin/cb [Drug Combination], voclosporin/cm [Drug Comparison], voclosporin/dt [Drug Therapy], AMG 811/ct [Clinical Trial], AMG 811/cm [Drug Comparison], AMG 811/sc [Subcutaneous Drug Administration], AMG 811/dt [Drug Therapy], all cause mortality, alopecia/si [Side Effect], biological therapy, bladder disease/si [Side Effect], bone disease/si [Side Effect], creatinine blood level, creatinine clearance, diarrhea/si [Side Effect], disease activity, dosage schedule comparison, drug dose comparison, drug dose increase, drug dose reduction, drug dose titration, drug megadose, drug withdrawal, end stage renal disease, gastrointestinal symptom/si [Side Effect], herpes zoster/si [Side Effect], human, immunoadsorption, immunosuppressive treatment, infection/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37602
Cochrane Database of Systematic Reviews
Click here for full text options
LibKey Link

المؤلفون: Apostolopoulos D., Morand E.F.

مصطلحات الفهرس: hydroxychloroquine/dt [Drug Therapy], immunosuppressive agent/dt [Drug Therapy], monoclonal antibody/dt [Drug Therapy], mycophenolic acid/dt [Drug Therapy], chemically induced, Lupus Erythematosus, Systemic/dt [Drug Therapy], belimumab, bone necrosis, cardiovascular disease, cataract, Cushing syndrome, diabetes mellitus, disease course, evidence based medicine, fragility fracture, human, pathophysiology, antirheumatic agent/dt [Drug Therapy], azathioprine/dt [Drug Therapy], glucocorticoid/ae [Adverse Drug Reaction], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/39553
Click here for full text options
LibKey Link